España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios syva sa - mycoplasma agalactiae, inactivado, cepa n84 - suspensiÓn inyectable - mycoplasma agalactiae, inactivado, cepa n84 3,16u elisa - vacunas bacterianas inactivadas (incluyendo micoplasma, clamidia y toxoide) - ovino; caprino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios syva sa - mycoplasma agalactiae, inactivado, cepa n84 - suspensiÓn inyectable - mycoplasma agalactiae, inactivado, cepa n84 4,23 u elisa - vacunas bacterianas inactivadas (incluyendo micoplasma, clamidia y toxoide) - ovino; caprino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp & dohme animal health s.l. - mycoplasma agalactiae, inactivado, cepa n-262 - emulsiÓn inyectable - mycoplasma agalactiae, inactivado, cepa n-262 70u elisa - vacunas bacterianas inactivadas (incluyendo micoplasma, clamidia y toxoide) - ovino; caprino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios ovejero s.a. - mycoplasma agalactiae inactivado, cepa ag 8 - suspensiÓn inyectable - mycoplasma agalactiae inactivado, cepa ag 8 0,93u elisa - vacunas bacterianas inactivadas (incluyendo micoplasma, clamidia y toxoide) - ovino; caprino

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

laboratorios hipra s.a. - mycoplasma gallisepticum - suspensiÓn inyectable - mycoplasma gallisepticum 1/8microaglutinación de anticuerpos-reacción lítica - micoplasma - gallinas ponedoras; pollos reproductores

Unión Europea - español - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - inmunológicos para suidos - los cerdos (de engorde) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kernfarm - mycoplasma synoviae, cepa ms-nev1, inactivada - emulsiÓn inyectable - mycoplasma synoviae, cepa ms-nev1, inactivada 1 x 10e10ufc - micoplasma - pollos

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

kernfarm - mycoplasma gallisepticum inactivado cepa nev40 - emulsiÓn inyectable - mycoplasma gallisepticum inactivado cepa nev40 40unidades inhibición de hemoaglutinación - micoplasma - pollos reproductores; gallina-pollitas futuras ponedoras

Unión Europea - español - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae strain ms-h - immunologicals para aves, viven de vacunas bacterianas - pollo - para la inmunización activa de futuro criador de pollos de engorde de pollos, el futuro de la capa de criador de pollos y futuro de la capa de pollos para reducir el aire sac lesiones y reducir el número de huevos con alteración en la formación de la cáscara del causada por mycoplasma synoviae.

Unión Europea - español - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cerdos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.